XCUBE
LIVE

Serial Number

79320193

Owner

Immatics Biotechnologies GmbH

Attorney

Anna Kurian Shaw

Filing Date

Feb 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

XCUBE Trademark

Serial Number: 79320193 • Registration: 8200099

XCUBE is a trademark filed by Immatics Biotechnologies GmbH on February 25, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Immatics Biotechnologies GmbH

Paul-Ehrlich-Strasse 15

Entity Type: 99

Trademark Details

Filing Date

February 25, 2021

Registration Date

April 7, 2026

Published for Opposition

February 17, 2026

Goods & Services

Medical and pharmaceutical consultancy services

Compilation of statistical data and models with respect to cancer treatment and cancer diagnosis

Computer programming in the medical, pharmaceutical and biotechnological field; database design in the medical, pharmaceutical and biotechnological field; maintenance of database software in the medical, pharmaceutical, and biotechnological field; programming of software for importing and managing data in the medical, pharmaceutical, and biotechnological field; information technology [IT] consulting services for the pharmaceutical and healthcare industries relating to data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; computer programming for data processing; conducting evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials in the field of pharmaceuticals for the treatment and prevention of cancer; providing scientific molecular and genomic information for medical and clinical research, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; research and development of medicines and diagnostic agents for cancer treatment and cancer diagnosis; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next-generation sequencing (NGS) with respect to the analysis and interpretation of genomic data obtained from cancer patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; research and development services in the field of immunology; none of the foregoing in connection with HVAC systems or components thereof

Recorded bioinformatics software for data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded graphical user interface software for data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded artificial intelligence and machine learning software for genome analysis, developing personal treatment strategies for patients with diagnosed cancer, analyzing, screening, identifying, quantifying, and interpreting data in the field of mass spectrometry and next-generation sequencing (NGS); electronic databases for bioinformatic purposes; next-generation sequencing (NGS) data processor; bioinformatics data processor; none of the foregoing in connection with HVAC systems or components thereof

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 7, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 7, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 17, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 6, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 6, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 6, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 8, 2025 CNRT
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 16, 2025 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 15, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 15, 2024 GNSL
SUSPENSION LETTER WRITTEN
Nov 15, 2024 CNSL
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 20, 2024 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 29, 2024 RCCK
ASSIGNED TO EXAMINER
Mar 29, 2024 DOCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 25, 2024 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 25, 2023 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 14, 2023 OPNX
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Feb 27, 2023 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 22, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 22, 2023 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 30, 2023 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 30, 2023 ERSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 28, 2022 RCSC
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 2, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 2, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 2, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 2, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 2, 2022 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Oct 7, 2022 NREP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 13, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
May 13, 2022 GNSL
SUSPENSION LETTER WRITTEN
May 13, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2022 CRFA
ASSIGNED TO LIE
May 10, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 6, 2022 ERSI
REFUSAL PROCESSED BY IB
Nov 29, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 8, 2021 RFCS
REFUSAL PROCESSED BY MPU
Nov 8, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 14, 2021 RFCR
SUSPENSION LETTER WRITTEN
Oct 13, 2021 CNSL
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Oct 7, 2021 RFWR
APPLICATION FILING RECEIPT MAILED
Sep 24, 2021 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 22, 2021 RFCR
SUSPENSION LETTER WRITTEN
Sep 21, 2021 CNSL
ASSIGNED TO EXAMINER
Sep 21, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 16, 2021 REPR